Key Facts

Invested since 2021
Based in International

About the company

PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring precision medicine benefits to all cancer patients. PreComb is pioneering breakthrough technologies to directly test the drug response of individual cancer patients, based on patient-derived 3D microtumors. For the first time, a fully automated point-of-care solution for determining drug sensitivity or resistance directly in the clinic is being developed. This offers the unique ability to routinely test entire portfolios of cancer drugs and drug combinations in large-scale, making the technology a universal tool from drug discovery to guiding therapies.

Do you want to

know more about this company?

Zum Artikel

Dr. Anke Caßing Principal

Dr. Anke CaßingPrincipal

PreComb in the news

Zum Artikel

News

26. April 2021

PreComb Therapeutics AG secures CHF 2.2 Mio seed financing to advance personalized medicine for cancer patients

More startups from Life Sciences